You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaNervous SystemProduct ClassPsychoanalepticsPharmacological SubgroupAnti-Dementia DrugsChemical SubgroupAnticholinesterasesCondition StudiedAlzheimer Disease
Sponsor Protocol NumberCR003145 // GAL-INT-11Enrollment974Data PartnerJohnson & Johnson% Female54.0%Mean/Median Age (Years)70.0% WhiteN/A
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2025-0352 : ALL-EMBRACED: clinicAL triaLs web-sErvice to Modify eligiBility cRiteria and pre-screening viA artifiCial intElligence methoDs
- 2024-0352 : Deciphering AD Etiology: A Synthesis of Trial and Observational Data
- 2022-5053 : Adverse events reported in association with APOE genotype during clinical trials
- 2021-4836 : Adverse events of acetylcholinesterase inhibitors - systematic review and meta-analysis of double-blind randomized controlled trials
- 2021-4743 : Machine Learning Approaches to Predicting Treatment Outcomes in Alzheimer's Disease
- 2021-4683 : The effects of systemic anti-infective concomitant medications on progression of neurological diseases
- 2020-4448 : Reanalysis of Alzheimer's Disease Clinical Trials Using Longitudinal Latent Trait Models
- 2020-4323 : Identification of biomarkers associated with Alzheimer's disease progression that correlate with responses to medications.
- 2017-1746 : Heterogeneity in relative treatment efficacy by age, sex, socioeconomic status and comorbidity
- 2016-0765 : Improving the statistical analysis of cognitive outcomes in randomised controlled trials: The 'Optimising the Analysis of Cognition' Collaboration